Welcome

Lennox Hill Hospital, NY, USA

Dr. Ana Franceschi serves as Director of Dementia Imaging at Lenox Hill Hospital/Northwell Health and is an Associate Professor of Radiology at the Barbara and Donald Zucker School of Medicine at Hofstra/Northwell. Dr. Franceschi has developed a special emphasis on the advancement of brain PET/MRI and hybrid imaging techniques in dementia and neurodegenerative disease. Dr. Franceschi was awarded the 2021 Foundation of the ASNR Boerger Research Fund for Alzheimer’s Disease and Neurocognitive Disorders for the project “[18F] PI-2620 in Primary Progressive Aphasia,” with the goal of characterizing biodistribution of abnormal tau accumulation in PPA subtypes using the novel second generation tracer PI-2620 and correlating these findings with clinical disease severity and neurodegeneration. She is also PI for the project “Utility of [18F] PI-2620 as Universal Biomarker for the A/T/N Classification of Dementia and Neurodegenerative Disease”, which aims to establish the efficacy of PI-2620 as a single, universal biomarker for the A/T/N classification scheme of dementia. In addition to multiple scientific publications on this topic, Dr. Franceschi is the lead editor of the textbook Hybrid PET/MR Neuroimaging: A Comprehensive Approach (Springer Nature, 2022). She serves as the Senior Editor for the Molecular Imaging section of the AJNR, Chair of the ACR’s Dementia Workgroup, and contributes to leadership decisions as a member of the AJNR and WJNM Editorial Boards.

Disclosures

Honoraria/Consultation fees from Biogen, Eisai, Eli Lilly, Roche, Siemens Healthineers, MIM Software, Cardinal Health, Life Molecular Imaging, Blue Earth Diagnostics, Icometrix, Cortechs, PeerView.

University of Alabama, Birmingham, USA

Jonathan McConathy, M.D., Ph.D., received a B.S. degree in Chemistry at the University of North Carolina at Chapel Hill. He then completed the Medical Scientist Training Program at Emory University with a Ph.D. in Neuroscience under the mentorship of Mark Goodman, Ph.D., and Michael Owens, Ph.D. He pursued postgraduate training at the Mallinckrodt Institute of Radiology (MIR) in St. Louis, Missouri through a residency in Diagnostic Radiology followed by a fellowship in Nuclear Medicine. Dr. McConathy then joined the faculty of MIR in July 2010 where he served as the Co-Director of the Radiology Research Residency.

Dr. McConathy joined UAB Department of Radiology in December 2015 and serves as the Director of the Division of Molecular Imaging and Therapeutics. In addition to clinical practice in Nuclear Medicine, he remains actively involved in the development and application of positron emission tomography (PET) tracers for oncology and neuroimaging as well as the use of simultaneous PET/MRI for both clinical indications and research.

His current research, clinical interests and area of expertise are multimodality molecular imaging including SPECT/CT, PET/CT and PET/MRI and PET tracer development and application for oncology and neuroimaging.

Disclosures

Honoraria from Novartis, Telix, Eli Lilly/Avid; Consulting fees from GE Healthcare, Novartis; and research support from Eli Lilly/Avid, GE Healthcare.

Other financial or material support

Clinical trial sponsors: Cytosite Biopharma, RayzeBio, Novartis, Telix, Fusion Pharmaceuticals, Clarity Pharmaceuticals

Nippon Medical School, Bunkyo City, Tokyo, Japan

Education and Professional Experiences

Director of Drug discovery Research and Cyclotron Center, Southern TOHOKU Research Institute for Neuroscience from 2020 to 2025. Professor of Department of Biofunctional Imaging, Fukushima Medical University from 2021 to 2025. Director of Clinical trials/Clinical research promotion office, Nippon Medical School, Clinical Imaging Center for Healthcare from Apr. 2025.

Other Professional Affiliation / Qualification:

Visiting Professor of Saitama Medical University.

Board certified specialist of Japanese Society of Radiology, Japanese Society of Nuclear Medicine, and Japanese Society of Dementia Research.

Publications Highlights:

417 English articles, 106 books (Japanese and English, editor 11), h-index 78.

Disclosures

Grants-in-Aid for Scientific Research:  Intramural Research Grant for Neurological and Psychiatric Disorders of the National Center of Neurology and Psychiatry.

Received Honoraria from PDRadiopharma.

Faculty of Medicine Siriraj Hospital, Bangkok, Thailand

Dr. Tanyaluck Thientunyakit is an Associate Professor in Nuclear Medicine. She got the Thai Board of Nuclear Medicine in 2004 and the Fellow of the Asian Nuclear Medicine Board in 2017. She is President of Quality Development in the Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University in Bangkok, Thailand. She is also The National Hybrid Imaging Ambassador to Thailand for the European Society for Hybrid, Molecular, and Translation Imaging, Board member of the Brain Imaging Council, Society of Nuclear Medicine Molecular Imaging, and Faculty Member of Asian Nuclear Medicine Board.

Dr. Thientunyakit has had experiences in clinical services, teachings, administration, research grants, journal reviews, and coordination for scientific activities at both national and international levels. Her special interests and publications are in Nuclear Medicine Applications in Oncology, Neurology, Thyroid Diseases, and Routine-to-Research for Quality Development in Radiology and Nuclear Medicine Services. She was an invited speaker at several academic conferences in Asian countries. She has collaborated with the IAEA and RCARO through many national and international projects, including collaborative research projects in neurology and cardiology. She received awards from National and International organizations, including the Ministry of Public Health, Thailand, RCARO, WFNMB, ECR, and SNMMI, for her academic and research activities.

Disclosures

Research grant from GC Healthcare Co, Thailand.

University of Turin, Italy

Silvia Morbelli is a Full Professor and head of Nuclear Medicine at the University of Turin. She holds a PhD in Applied Neurosciences. Prof Morbelli has made contributions related to the use of neuroimaging tools as diagnostic and prognostic biomarkers in the earliest and preclinical stages of Neurodegenerative Dementia and Parkinsonian Syndromes. She is especially interested in the use of Molecular Imaging to disclose networks underlying different clinical phenotypes as well as brain reserve in Alzheimer’s and Lewy Body Diseases. She served as Chair of the Neuroimaging Committee of the European Association of Nuclear Medicine from 2020 to 2022.

Disclosures

Silvia Morbelli has received speaker honoraria from Eli-Lilly, Life Molecular Imaging, Novartis and GE Healthcare.

University Hospital of Cologne, Germany

Alexander Drzezga studied human medicine at the Ludwig Maximilians University and the Technical University of Munich, obtained a license for medical practice, and took up residency at the Department of Nuclear Medicine of the Technical University of Munich.

In 2002 Drzezga specialized in nuclear medicine, and was a Consultant at the Department before becoming Assistant Professor at the Technical University. Since 2012 he has been Professor and Chair of the Department of nuclear medicine at the University Hospital Cologne, and he is currently the chair of the Department of Nuclear Medicine at the University Hospital Cologne and affiliated with the German Center for Neurodegenerative Disorders (DZNE) and the Institute for Neuroscience and Medicine (INM) at the Research Center Juelich. In 2018 he became Director at the INM.

Drzezga’s research focus is on the application of multimodal and molecular imaging procedures to investigate neurodegenerative disorders and their interrelation to the network architecture of the brain. He is a member of the AMYPAD project and is a Principal Investigator at the AMYPAD site in Cologne, Germany.

Disclosures

Alexander Drzezga has received grant funding and research support from Siemens Healthineers, Sofie, Novartis/AAA, Life Molecular Imaging, and Deutsche Forschungsgesellschaft; and honoraria or consulting fees from GE Healthcare, Biogen, Japan Radiological Society, Novartis, Lilly Deutschland, Peer View Institute for Medical Education Inc., Bayer Vital GmbH, European Research Council, Invicro, and International Atomic Energy Agency.

He holds Stocks, shares or equity in Siemens Healthineers and Lantheus Holding. In addition he has applied for patent for 2-Alkoxy-6-[18F]Fluoronicotinoyl substituted Lys-C(O)-Glu derivatives as efficient probes for imaging of PSMA expressing tissues (Patent No.: EP3765097A1). He is Associate Editor for The Journal of Nuclear Medicine, Nuklearmedizin/NuclearMedicine, and Nuklearmedizinische Hirnbildgebung in “Angewandte Nuklearmedizin”.

Lennox Hill Hospital, NY, USA

Dr. Ana Franceschi serves as Director of Dementia Imaging at Lenox Hill Hospital/Northwell Health and is an Associate Professor of Radiology at the Barbara and Donald Zucker School of Medicine at Hofstra/Northwell. Dr. Franceschi has developed a special emphasis on the advancement of brain PET/MRI and hybrid imaging techniques in dementia and neurodegenerative disease. Dr. Franceschi was awarded the 2021 Foundation of the ASNR Boerger Research Fund for Alzheimer’s Disease and Neurocognitive Disorders for the project “[18F] PI-2620 in Primary Progressive Aphasia,” with the goal of characterizing biodistribution of abnormal tau accumulation in PPA subtypes using the novel second generation tracer PI-2620 and correlating these findings with clinical disease severity and neurodegeneration. She is also PI for the project “Utility of [18F] PI-2620 as Universal Biomarker for the A/T/N Classification of Dementia and Neurodegenerative Disease”, which aims to establish the efficacy of PI-2620 as a single, universal biomarker for the A/T/N classification scheme of dementia. In addition to multiple scientific publications on this topic, Dr. Franceschi is the lead editor of the textbook Hybrid PET/MR Neuroimaging: A Comprehensive Approach (Springer Nature, 2022). She serves as the Senior Editor for the Molecular Imaging section of the AJNR, Chair of the ACR’s Dementia Workgroup, and contributes to leadership decisions as a member of the AJNR and WJNM Editorial Boards.

Disclosures

Honoraria/Consultation fees from Biogen, Eisai, Eli Lilly, Roche, Siemens Healthineers, MIM Software, Cardinal Health, Life Molecular Imaging, Blue Earth Diagnostics, Icometrix, Cortechs, PeerView.

University of Alabama, Birmingham, USA

Jonathan McConathy, M.D., Ph.D., received a B.S. degree in Chemistry at the University of North Carolina at Chapel Hill. He then completed the Medical Scientist Training Program at Emory University with a Ph.D. in Neuroscience under the mentorship of Mark Goodman, Ph.D., and Michael Owens, Ph.D. He pursued postgraduate training at the Mallinckrodt Institute of Radiology (MIR) in St. Louis, Missouri through a residency in Diagnostic Radiology followed by a fellowship in Nuclear Medicine. Dr. McConathy then joined the faculty of MIR in July 2010 where he served as the Co-Director of the Radiology Research Residency.

Dr. McConathy joined UAB Department of Radiology in December 2015 and serves as the Director of the Division of Molecular Imaging and Therapeutics. In addition to clinical practice in Nuclear Medicine, he remains actively involved in the development and application of positron emission tomography (PET) tracers for oncology and neuroimaging as well as the use of simultaneous PET/MRI for both clinical indications and research.

His current research, clinical interests and area of expertise are multimodality molecular imaging including SPECT/CT, PET/CT and PET/MRI and PET tracer development and application for oncology and neuroimaging.

Disclosures

Honoraria from Novartis, Telix, Eli Lilly/Avid; Consulting fees from GE Healthcare, Novartis; and research support from Eli Lilly/Avid, GE Healthcare.

Other financial or material support

Clinical trial sponsors: Cytosite Biopharma, RayzeBio, Novartis, Telix, Fusion Pharmaceuticals, Clarity Pharmaceuticals

Nippon Medical School, Bunkyo City, Tokyo, Japan

Education and Professional Experiences

Director of Drug discovery Research and Cyclotron Center, Southern TOHOKU Research Institute for Neuroscience from 2020 to 2025. Professor of Department of Biofunctional Imaging, Fukushima Medical University from 2021 to 2025. Director of Clinical trials/Clinical research promotion office, Nippon Medical School, Clinical Imaging Center for Healthcare from Apr. 2025.

Other Professional Affiliation / Qualification:

Visiting Professor of Saitama Medical University.

Board certified specialist of Japanese Society of Radiology, Japanese Society of Nuclear Medicine, and Japanese Society of Dementia Research.

Publications Highlights:

417 English articles, 106 books (Japanese and English, editor 11), h-index 78.

Disclosures

Grants-in-Aid for Scientific Research:  Intramural Research Grant for Neurological and Psychiatric Disorders of the National Center of Neurology and Psychiatry.

Received Honoraria from PDRadiopharma.

Faculty of Medicine Siriraj Hospital, Bangkok, Thailand

Dr. Tanyaluck Thientunyakit is an Associate Professor in Nuclear Medicine. She got the Thai Board of Nuclear Medicine in 2004 and the Fellow of the Asian Nuclear Medicine Board in 2017. She is President of Quality Development in the Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University in Bangkok, Thailand. She is also The National Hybrid Imaging Ambassador to Thailand for the European Society for Hybrid, Molecular, and Translation Imaging, Board member of the Brain Imaging Council, Society of Nuclear Medicine Molecular Imaging, and Faculty Member of Asian Nuclear Medicine Board.

Dr. Thientunyakit has had experiences in clinical services, teachings, administration, research grants, journal reviews, and coordination for scientific activities at both national and international levels. Her special interests and publications are in Nuclear Medicine Applications in Oncology, Neurology, Thyroid Diseases, and Routine-to-Research for Quality Development in Radiology and Nuclear Medicine Services. She was an invited speaker at several academic conferences in Asian countries. She has collaborated with the IAEA and RCARO through many national and international projects, including collaborative research projects in neurology and cardiology. She received awards from National and International organizations, including the Ministry of Public Health, Thailand, RCARO, WFNMB, ECR, and SNMMI, for her academic and research activities.

Disclosures

Research grant from GC Healthcare Co, Thailand.